Ascendis Pharma A/S (NASDAQ:ASND) Hits New 52-Week High - Here's What Happened

Key Points

• Ascendis Pharma shares hit a new 52-week high, trading as high as $250.74 (last at $246.1450) on Monday with about 100,005 shares changing hands and the stock up roughly 1.9%.
• Analysts are broadly bullish — the consensus rating is a “Moderate Buy” with an average target of $289.89, and several firms (Barclays, Wells Fargo, Stifel) have issued high price targets up to $342 and overweight/outperform ratings.
• Company fundamentals show a market cap of about $15.2B and a negative P/E; Ascendis reported Q4 EPS of -$0.64 (missing estimates) but revenue of $290.4M (slightly above expectations), and its lead product is the once‑weekly growth hormone Skytrofa built on the TransCon platform.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) shares reached a new 52-week high during trading on Monday . The company traded as high as $250.74 and last traded at $246.1450, with a volume of 100005 shares trading hands. The stock had previously closed at $239.28.

Analyst Upgrades and Downgrades

ASND has been the topic of a number of analyst reports. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research note on Wednesday, March 4th. Wedbush reaffirmed an "outperform" rating and set a $273.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday. Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an "overweight" rating in a research note on Tuesday, January 20th. Barclays began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $342.00 price objective on the stock. Finally, Royal Bank Of Canada increased their price objective on Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an "outperform" rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $289.89.

Ascendis Pharma A/S Stock Up 1.9%

The company has a market cap of $15.22 billion, a P/E ratio of -55.44 and a beta of 0.49. The firm has a 50 day moving average of $227.49 and a 200-day moving average of $215.28.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The business had revenue of $290.38 million during the quarter, compared to analyst estimates of $285.35 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its position in Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company's stock valued at $249,000 after acquiring an additional 55 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Ascendis Pharma A/S by 1.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company's stock worth $1,209,000 after purchasing an additional 58 shares in the last quarter. Certuity LLC boosted its position in shares of Ascendis Pharma A/S by 5.7% in the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company's stock worth $249,000 after purchasing an additional 63 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 15.1% in the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company's stock worth $117,000 after purchasing an additional 72 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Ascendis Pharma A/S by 0.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company's stock worth $2,103,000 after purchasing an additional 73 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.